 | Global Oncology Trial Management Strategies This complimentary white paper from Novella Clinical will help small- to mid-size pharma and biotech companies develop effective operational study plans, create robust and realistic feasibility studies and navigate regulatory submissions across multiple countries. Download: Global Oncology Trials - Planning for Success. | | Stem cell discovery shows promise in tissue regeneration BMI1, a protein essential in the self-renewing cell divisions of adult stem cells, can be prevented from spawning potentially defective or misplaced cells that hinder tissue regeneration, according to a study in Nature Cell Biology. Researchers believe that the manipulation of BMI1 and other regulatory molecules may one day be useful in the development of techniques that need specialized cell development switches for the treatment of tissue damage brought about by injury, disease or aging. Yahoo/Asian News International (7/21) | Funding round brings in $1.4M for lymphoma immunotherapy developer Bullet Biotechnology secured $1.4 million in its latest funding round, a securities filing showed. The California-based firm is developing an active immunotherapy designed to mobilize the immune system to fight a marker of B-cell lymphoma. The drug candidate could enter clinical trials in early 2015, CEO Willie Quinn said. MedCityNews.com (7/22)  | EvaluatePharma World Preview 2013, Outlook to 2018
In this sixth annual edition report, Evaluate brings together many of our analyses to provide top level insight into the expected performance of the industry between now and 2018. The report highlights trends in Rx drug sales, patent risk, R&D spend and sales by therapy area as well as a brief review of 2012 performance. Download your complimentary report now. |
 | S. Korea will invest in global pharmaceutical expansion South Korea plans to invest $8.9 billion to develop 20 new drugs in collaboration with local drug manufacturers. The plan is part of a five-year effort to develop the country into a global pharmaceutical center. It includes tax breaks for research and development, and a fund valued at around $447 million to help Korean companies expand internationally. Yonhap News Agency (South Korea) (7/21) | Monsanto's Europe withdrawal disappoints farmer in England Farmer and former U.K. National Farmers Union Vice President Paul Temple of Driffield, England, said his past participation in a biotech field trial left him particularly disappointed at Monsanto's decision to withdraw regulatory applications in Europe. "Look at maize production across North and South America. Those farmers and those countries have effectively responded to the food security, the food supply debate. And Europe has got itself stuck in a strange position where we're depending on GM crops for feeding everybody, but we aren't providing the choice," he said. Bloomberg (7/19) | | Industrial & Environmental | Fuels America responds to oil industry with its own ad campaign Fuels America kicked off a new ad campaign highlighting the ability of the Renewable Fuel Standard to boost fuel choices for consumers. The ads also indicate that the oil industry's opposition to the RFS is rooted in a desire to maintain its hold on the fuel market. Bob Dinneen, president and CEO of the Renewable Fuels Association, maintains there is no need for legislation to address concerns about the RFS because the Environmental Protection Agency has "more than enough flexibility" to deal with them. The Hill/E2 Wire blog (7/22), DomesticFuel.com (7/22) | Save on energy costs through BIO's newest cost-savings program BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more. |  | Opinions are made to be changed -- or how is truth to be got at?" -- Lord Byron, British poet | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment